Scholarlink

Introduction <p>There is little real-world evidence on semaglutide effectiveness in the United Arab Emirates (UAE), despite the high local burden of type 2 diabetes (T2DM) and obesity. The aim of this study was to evaluate real-world cardiometabolic outcomes and predictors of response following initiation of semaglutide in a tertiary endocrine clinic.</p> Methods <p>This was a retrospective, observational cohort study of adults with T2DM initiating once-weekly subcutaneous semaglutide (June 2022 to January 2025). Primary outcomes were changes in glycated hemoglobin (HbA1c), body weight, and systolic blood pressure (SBP) at 6 and 12 months. Responder and composite endpoints were assessed at 12 months. Predictors of glycemic (HbA1c reduction ≥ 1%) and composite response (HbA1c reduction ≥ 1% and ≥ 5% weight loss) were analyzed by multivariable logistic regression.</p> Results <p>In total, 278 patients were included. Adjusted HbA1c decreased by −0.89% (95% confidence interval (CI) −1.07 to −0.70) at 6 months and −0.71% (95% CI −0.91 to −0.50) at 12 months (both <i>p</i> &lt; 0.001). Weight decreased by −3.09 kg (−4.19 to −2.00) and −4.77 kg (−6.00 to −3.53) at 6 and 12 months, respectively (<i>p</i> &lt; 0.001). SBP decreased by −3.56 mmHg (−6.17 to −0.96; <i>p</i> = 0.007) at 6 months. Overall, 39% achieved an HbA1c reduction ≥ 1%, 43% achieved ≥ 5% weight loss, and 23% achieved the composite endpoint at 12 months. Higher baseline HbA1c predicted HbA1c response (odds ratio [OR] 1.85; 95% CI 1.26 to 2.88).</p> Conclusion <p>Semaglutide improved glycemia and weight and resulted in modest reductions in SBP in real-world practice. These findings support semaglutide as an effective component of cardiometabolic risk reduction strategies in adults with T2DM in the region, especially in those with at-risk glycemic profiles.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cardiometabolic Effects of Semaglutide in Individuals with Type 2 Diabetes in the United Arab Emirates: Real-World 12-Month Outcomes and Predictors of Response

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月15日

查看全文
  • Muhammad Hamid Siddique Mian,
  • Kholood Abdulla Hasan Abdulla Janahi,
  • Afnan Tayeb,
  • Fathima Musfira Mohamad Musaffar,
  • Nur Al Sheykh Khalil,
  • Sarah Hisham Al Toubah,
  • Abdul Moen Abdul Karim,
  • Ahlam Almarzooqi,
  • Fardeen Mohammad Sayfoo,
  • Ahmed Hamadeh,
  • Mohannad Abdulla Hasan Abdulla Janahi,
  • Sobia Siddiq

摘要

Introduction

There is little real-world evidence on semaglutide effectiveness in the United Arab Emirates (UAE), despite the high local burden of type 2 diabetes (T2DM) and obesity. The aim of this study was to evaluate real-world cardiometabolic outcomes and predictors of response following initiation of semaglutide in a tertiary endocrine clinic.

Methods

This was a retrospective, observational cohort study of adults with T2DM initiating once-weekly subcutaneous semaglutide (June 2022 to January 2025). Primary outcomes were changes in glycated hemoglobin (HbA1c), body weight, and systolic blood pressure (SBP) at 6 and 12 months. Responder and composite endpoints were assessed at 12 months. Predictors of glycemic (HbA1c reduction ≥ 1%) and composite response (HbA1c reduction ≥ 1% and ≥ 5% weight loss) were analyzed by multivariable logistic regression.

Results

In total, 278 patients were included. Adjusted HbA1c decreased by −0.89% (95% confidence interval (CI) −1.07 to −0.70) at 6 months and −0.71% (95% CI −0.91 to −0.50) at 12 months (both p < 0.001). Weight decreased by −3.09 kg (−4.19 to −2.00) and −4.77 kg (−6.00 to −3.53) at 6 and 12 months, respectively (p < 0.001). SBP decreased by −3.56 mmHg (−6.17 to −0.96; p = 0.007) at 6 months. Overall, 39% achieved an HbA1c reduction ≥ 1%, 43% achieved ≥ 5% weight loss, and 23% achieved the composite endpoint at 12 months. Higher baseline HbA1c predicted HbA1c response (odds ratio [OR] 1.85; 95% CI 1.26 to 2.88).

Conclusion

Semaglutide improved glycemia and weight and resulted in modest reductions in SBP in real-world practice. These findings support semaglutide as an effective component of cardiometabolic risk reduction strategies in adults with T2DM in the region, especially in those with at-risk glycemic profiles.